Share Name Share Symbol Market Type Share ISIN Share Description
Angle Plc LSE:AGL London Ordinary Share GB0034330679 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  -2.00 -2.04% 96.00 248,077 09:06:04
Bid Price Offer Price High Price Low Price Open Price
95.00 97.00 98.00 95.00 98.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 1.01 -17.36 -6.67 226
Last Trade Time Trade Type Trade Size Trade Price Currency
09:12:08 O 10 96.96 GBX

Angle (AGL) Latest News

More Angle News
Angle Investors    Angle Takeover Rumours

Angle (AGL) Discussions and Chat

Angle Forums and Chat

Date Time Title Posts
30/6/202209:05ANGLE PLC - 2019 THREAD - LIQUID BIOPSY COMPANY13,093
30/6/202200:03ANGLE PLC IT'S A SPOOF282
29/6/202216:08Angle PLC179
21/6/202212:49ANGLE (AGL) Strategic Move3
21/6/202208:48Angle PLC 201130,123

Add a New Thread

Angle (AGL) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Angle trades in real-time

Angle (AGL) Top Chat Posts

Angle Daily Update: Angle Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AGL. The last closing price for Angle was 98p.
Angle Plc has a 4 week average price of 88.50p and a 12 week average price of 88.50p.
The 1 year high share price is 163.50p while the 1 year low share price is currently 71.50p.
There are currently 235,143,050 shares in issue and the average daily traded volume is 732,561 shares. The market capitalisation of Angle Plc is £223,385,897.50.
amaretto1: I'm not comparing STX with AGL Stating a point !! It's like a kiss of death ... you wait years and it makes absolutely no diffrence ... unless American company...I'm not trading AGL and have been here for nearly 2 years .... The share price looks very vunerable to me at present with a heavy seller to boot
purchaseatthetop: Sk. This contract simply tees the share price up ready for the next RNS where investors can see this is a contract snowball. The fact that AN said that this one took 9 months to negotiate means we may wait for a short while but when the next arrives the concept will be proven and 5he share price will explode. Just my view of course.
alloa2003: This share price is madness. They have waited years for FDA approval, got it and the shares went up and all the way back down. I appreciate, having watched this for years, the company may have been expected to hit the ground running with revenue sources but its not that easy. No company in their right mind would commit until approval was in place. The backup plan is there; if AGL cant bring in the revenue, someone else will swoop, take them over and full utilise the technology and FDA approval. At this level surley a long term no brainer?
tday: SA. Sounds plausible, except if there were to be an offer from Abbott in the near future, a figure of 220-250p would probably succeed, against the current share price of 93p. Its not necessarily what AN wants, it's what the majority of shareholders would accept. Maybe if the share price improves over time, a higher price would need to be made. In the meantime, if the share price languishes at its current level, 250p or thereabouts would get my vote.
sicilian_kan: Angle is not expected to turn an overall company profit (net income) until 2028 according to Berenberg. It too has funding needs that will significantly exceed revenues for a number of years, despite an attractive gross profit on sales not that dissimilar to EXAS's. Hopefully the funding need can be met as much as possible by deals with Abbott and others, but that is not yet finalised, the pool of possible participants for funding Angle is diminished in the current climate (I cannot see EXAS spending large amounts of upfront cash at AGL now for example) and there is uncertainty as to the amount that Angle would get up front in any collaboration with Abbott. Once there is one of the following, then the prospects for Angle will be great and the share price will turn: (a) commercial progress by way of significant new contracts or a deal with Abbott; (b) clarity about funding beyond Q2 2023 or (c) signs that the economic crisis and market sentiment is turning. But at the moment, the above have (in the current climate) clouded the short term prospects here (with a fall from 160p to the mid 90s, that regrettably, in the current circumstances, has not surprised). Anyone watching on the sidelines of course risks missing out on the possibility of a transformative event - and yes they could occur even in the short term. Fully acknowledge that.
drums1: I have deliberately not looked at the share price or this board for a while so forgive me if this has been said before recently. I don't want to hear any reasons for or against why the share price is what is it. I just want to make the following points. . 1 ... There are no new shares to buy. 2 ... The only shares available are from existing holders selling (Go figure.) 3 ... Every share that has become available has been snapped up by the end of the day. 4 ... This is a very popular share. . In any legitimate market, all the above would send the price up. No excuses. This is fast becoming worthy of a criminal investigation. MM = Mafia mod.
fraybentos2: how i was mocked on here for saying that the share price would go below the pre fda price this year i also said the share price was going to fall below 100p at some point this year again i was mocked now mug punters have to face the reality
quayae: I first invested in AGL because of a business they had called Geomerics. This went on to be sold to ARM. The tech was a major advancement in computer games and the IP was very valuable. Similar to Parsortix for cancer. If this was Parsortix on AIM rather than AGL I might agree that AN would build a (you said the next big) pharma company but that's not the background or purpose of AGL. As you point out too PATT, AN and AGL experience is to commercialise IP and they have done a good job of it so far. I would expect the share price of AGL to be higher currently based on the value of the IP, and I'm comfortable at re-buy prices I've taken recently also, but I don't see AGL being bought out as much as Parsortix being sold out. Is there a risk at the lower prices that AGL itself splits out Parsortix and raises money separately and we are left holding the AGL shares? I don't know and wonder what more experienced accountants and share dealers think?
henley2: What a car crash of an interview. He’s not interested in short term performance. Fine. The share price will be back below 100p at this rate, followed by the inevitable capital raise. Well, as a long suffering shareholder who has financed the company for 6+ years in order to get FDA clearance I want a financial return, and hopefully before I’m 6 foot underground. Newland’s vision is very laudable but not suited to the UK market, and especially not AIM. Time for him to tap NASDAQ, or partnership with a large pharmaceutical/biotech to finance the next stage of his vision. He gives the impression he couldn’t give a toss about the share price and more interested in his legacy.
mikepompeyfan: This is the post - Current share price levels are not surprising. I took the view in mid April (see the link) that 150p to 164p+ would be the share price post FDA approval back when Exact Sciences had a depressed market cap of $11.6bn and when Guardant had a depressed market cap of $7.1bn. Those figures have now dropped even further to $8.2bn and $4.0bn respectively, so lower figures here are also justified. The share price will increase and stabilise higher only when either sector sentiment turns and / or significant and imminent revenues are due or expected. That may arrive with Abbott news (or it may not if the up front is not as high as some here hope for). It may also arise if they nail several large contracts or if the ovarian data is extremely compelling. But at present the extent of the revenues due this next 12 months is unknown (and possibly low for the current market cap) and the extent of monies needed by Angle in that same period is - proportionate to its revenues - relatively high. It is up to the company to justify the current share price (or higher). It has the chance with Abbott, ovarian data, CLIA and new contracts but as yet we merely hope and expect that such news is good - and in today’s market more than hope or expectation is needed to rise significantly from these levels.
Angle share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220630 08:29:32